Stock events for Zevra Therapeutics, Inc. (ZVRA)
ZVRA's stock has trended up by 0.34% in the past six months and increased by 20.57% over the last year as of March 4, 2026. There was a 26% loss in September 2025, although the stock had gained 24% in the year leading up to that point. The company held its Q3 2025 earnings call on November 5, 2025, and the Q4 and full-year 2025 financial results call is scheduled for March 9, 2026. The company participated in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025, and the J.P. Morgan 44th Annual Healthcare Conference on January 15, 2026.
Demand Seasonality affecting Zevra Therapeutics, Inc.’s stock price
There is no explicit data indicating demand seasonality for Zevra Therapeutics, Inc.'s products and services. Stock price seasonality analysis suggests June has the highest probability of positive returns, while March may not be an ideal month for investment.
Overview of Zevra Therapeutics, Inc.’s business
Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited treatment options. The company's portfolio includes commercial products like MIPLYFFA for Niemann-Pick disease type C, OLPRUVA for urea cycle disorders, and AZSTARYS for ADHD. Its pipeline features investigational candidates such as Celiprolol for Vascular Ehlers-Danlos Syndrome, KP1077 for rare sleep disorders, and KP879 for Stimulant Use Disorder.
ZVRA’s Geographic footprint
Zevra Therapeutics has a strong domestic focus, with revenues from MIPLYFFA and OLPRUVA derived from the United States market, and is pursuing opportunities for geographic expansion.
ZVRA Corporate Image Assessment
Zevra Therapeutics' brand reputation is positively influenced by the successful launch and performance of MIPLYFFA, indicated by strong U.S. sales and patient enrollment. The company's focus on unmet medical needs and patient-centric mission contribute to a favorable public image, further bolstered by financial highlights such as increased revenue and improved net income in Q3 2025.
Ownership
Zevra Therapeutics, Inc. is primarily owned by institutional shareholders (67.72%), followed by Zevra Therapeutics insiders (22.75%), and retail investors (9.53%). BlackRock, Inc., Woodline Partners LP, and Vanguard Group Inc are major institutional owners. Delaware Street Capital Master Fund LP is the largest individual shareholder. Insider buying activity has been observed.
